Cipro HC

Cipro HC is a brand name of ciprofloxacin/hydrocortisone otic, approved by the FDA in the following formulation(s):

CIPRO HC (ciprofloxacin hydrochloride; hydrocortisone - suspension/drops; otic)

• 
  Manufacturer: ALCON PHARMS LTD
  
  Approval date: February 10, 1998
  
  Strength(s): EQ 0.2% BASE;1% ^[RLD]

Has a generic version of Cipro HC been approved?

No. There is currently no therapeutically equivalent version of Cipro HC available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cipro HC. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Method of treating otitis with ciprofloxacin-hydrocortisone suspension
  Patent 5,843,930
  Issued: December 1, 1998
  Inventor(s): Purwar; Shivaji & Goldman; David
  Assignee(s): Bayer Corporation
  The invention is directed to a method of treating otitis which comprises introducing an antibacterially-effective amount of a composition comprising a non-ototoxic, topical, otic pharmaceutic composition comprising (a) ciprofloxacin in aqueous solution in an amount effective for antibacterial action; (b) a non-ionic viscosity augmenter unaffected by pH and ionic level, said viscosity augmenter being present in an amount effective for augmenting viscosity of the composition to a viscosity greater than that of water, said viscosity augmenter being at least 85% hydrolyzed polyvinyl alcohol; (c) a non-ototoxic preservative present in an amount effective for antibacterial action, the preservative being benzyl alcohol; (d) water sufficient to produce an aqueous composition; (e) hydrocortisone in aqueous suspension in an amount effective for anti-inflammatory action; (f) lecithin in an amount effective for enhancing suspension of other constituents in the composition; and (g) polysorbate ranging from polysorbate 20 to 80 in an amount effective for spreading the preparation on a hydrophobic skin surface to the site of infection or inflammation.
  
  Patent expiration dates:
  
  
  • June 6, 2015
    
    ✓ 
    Patent use: METHOD OF TREATING OTITIS
  
  



• 
  Ciprofloxacin-hydrocortisone suspension
  Patent 5,965,549
  Issued: October 12, 1999
  Inventor(s): Purwar; Shivaji & Goldman; David
  Assignee(s): Bayer Aktiengesellschaft
  The invention is directed to an aqueous non-ototoxic, topical, otic pharmaceutical composition of matter for treating a mammal consisting essentially of: ciprofloxacin or a pharmaceutically acceptable salt thereof in aqueous solution in an amount effective for antibacterial action; hydrocortisone or a pharmaceutically acceptable salt thereof in an amount effective as an anti-inflammatory agent; polyvinyl alcohol at least about 85% hydrolyzed in an amount effective to suspend the hydrocortisone in solution; water sufficient to produce an aqueous composition; benzyl alcohol in an amount effective for antibacterial action; lecithin in an amount effective for enhancing suspension of other constituents in the composition; and polysorbate ranging from polysorbate 20 to 80 in an amount effective for spreading the preparation on a hydrophobic skin surface to the site of infection or inflammation.
  
  Patent expiration dates:
  
  
  • June 6, 2015
    
    ✓ 
    Drug product
  
  

See also...

• Cipro HC Otic Consumer Information (Wolters Kluwer)
• Cipro HC Consumer Information (Cerner Multum)
• Cipro HC Advanced Consumer Information (Micromedex)
• Ciprofloxacin/Hydrocortisone Consumer Information (Wolters Kluwer)
• Ciprofloxacin and hydrocortisone otic Consumer Information (Cerner Multum)
• Ciprofloxacin and hydrocortisone Otic Advanced Consumer Information (Micromedex)